Justin Ferdinandus
@jusferdinandus
Followers
176
Following
862
Media
29
Statuses
295
#EarlyCareer Physician Scientist @UKKoeln 🇩🇪 with interest in Lymphoma 🩸and oncologic imaging 📸during the day | Guitarist 🎸at night
Köln, Deutschland
Joined April 2021
CONGRESS | #ASH24 | Justin Ferdinandus @jusferdinandus @UKKoeln shares results from the phase II portion of the GHSG HD21 trial of PET-guided BrECADD in older patients with advanced-stage cHL. At a median FU of 23 mo, 12 mo PFS 95.1%, 24 mo PFS 91.5, 12 mo OS 96.2%, 24 mo OS
0
9
16
New Episode! Tune in for #ASCO24 #EHA24 #Lymphoma updates with @gloria_iacoboni, where we discuss: STARGLO ECHO HD-21 EPCORE-NHL 5 EPCOR-CLL 1 and more! https://t.co/rqrovKmUXq
@Eddie_Cliff Check out this short clip on critical appraisal of STARGLO results! #lymsm
0
13
33
0
0
1
🚨 HD21 results now finally published in the @TheLancet : BrECADD is better tolerated and more efficient than eBEACOPP as PET-guided treatment for patients with adv. Hodgkin Lymphoma! #lymsm
3
11
53
Top quality session with great speakers on Hodgkin lymphoma at @EHA_Hematology 2024 just started.
0
3
13
I just can’t recommend #CRTH highly enough. Apply now, thank me later! Huge thanks to @EHA_Hematology for creating this platform.
#EHA2024 includes many presentations of @EHA_Hematology #CRTH alumni providing a great platform for #earlycareer hematologists to present their #research and #expertise, diversifying the speakers in career stage and age #careerdevelopment #DEI #hematology #mentoring @young_eha
0
0
6
Going from #CRTH scholar to faculty, @DottorClaudio talks about his experience following the program and what new scholars can expect. Tune in soon for the full video. The call for Clinical Research Training in hematology is now open: https://t.co/LEELh70Lqx
0
6
18
I can't recommend highly enough this amazing opportunity for training in clinical trial design and delivery by @EHA_Hematology Being part of the #CRTH24 cohort has been a fantastic experience so far Do apply below with a clinical trial idea ⬇️⬇️⬇️ https://t.co/9lk1jSRKnX
ehaweb.org
2
11
33
Medizinforschungsgesetz: Akademische Forschung bislang unberücksichtigt https://t.co/meaogWvEgm via @dt_aerzteblatt
aerzteblatt.de
0
5
3
Neues Forschungsgebäude Translational Research for Infectious Diseases and Oncology (TRIO) an der #Uniklinik #Köln eingeweiht: Das TRIO vereint Forschung zu #Infektionskrankheiten und #Onkologie und fungiert als interdisziplinärer Think Tank. https://t.co/9QLR8BnzMP
0
5
20
#Lymphom-Forschung: Die Else-Kröner-Fresenius-Stiftung hat ein Exzellenzstipendium an Priv.-Doz. Dr. Paul Bröckelmann, Facharzt für Innere Medizin, Hämatologie und Onkologie an der Klinik I für Innere Medizin, vergeben. @EKFStiftung @BroeckelmannPJ @MPIAGE
https://t.co/d6tYSJmmx1
2
5
30
Hit hard and remove treatment – this treatment strategy in #Hodgkin Lymphoma promises less fatigue and less sick-leave - Never compromise with curative treatment but PET guided stop also ⬇️ fatigue @BroeckelmannPJ @graham74GC
1
3
13
The 13th International Symposium on Hodgkin Lymphoma (ISHL13) will be held October 26-28, 2024 in Cologne 📅 Visit https://t.co/CoNV9UOZZB for info on early-bird registration🐦🪪, abstract submission 📝, the stellar ISHL13 scientific committee 🌟 & a first program outline🗓️
2
14
33
Radiotherapy remains “the most effective single agent in the treatment of lymphomas” -James Armitage, former ASCO president & highly regarded lymphoma leader Thrilled to have trained at UNMC, a leader in RT-accommodating HL/NHL approaches, guided by Dr. Armitage! #ASH23 #radonc
@ChelseaPinnix @aallam_mo @MDAndersonNews @JillGunther @BouthainaDabaja @suwusan Radiation therapy remains one of the most effective "drugs" in treating lymphoma #ASH23 #lymsm #radonc
4
22
60
Parallel to a fantastic #CLL session #ASH23, the primary analysis of the RT1 study just went online @NatureMedicine: High efficacy + tolerability of combined PD1+BTK inhibition with tislelizumab+zanubrutinib in patients with Richter-Transformation https://t.co/gpYrcxVcCx
nature.com
Nature Medicine - In a large single-arm phase 2 trial, the anti-PD-1 inhibitor tislelizumab combined with the next-generation BTK inhibitor zanubrutinib had an overall response rate of 58.3% and...
9
19
86